SNY – Sanofi
Float Short %
0.35
Margin Of Safety %
33
Put/Call OI Ratio
1.23
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.3
Price
47.48
Target Price
56.9
Analyst Recom
1.83
Performance Q
-3.3
Relative Volume
1.47
Beta
0.43
Ticker: SNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-07 | SNY | 48.38 | 1.71 | 0.24 | 80871 |
| 2026-01-08 | SNY | 48.12 | 1.49 | 0.03 | 85663 |
| 2026-01-09 | SNY | 49.02 | 1.41 | 0.12 | 87824 |
| 2026-01-12 | SNY | 47.6 | 1.39 | 0.08 | 88475 |
| 2026-01-13 | SNY | 47.2 | 1.51 | 0.82 | 85792 |
| 2026-01-14 | SNY | 47.94 | 1.50 | 0.17 | 86024 |
| 2026-01-15 | SNY | 47.47 | 1.41 | 2.50 | 88446 |
| 2026-01-16 | SNY | 46.6 | 1.33 | 0.36 | 85769 |
| 2026-01-20 | SNY | 45.73 | 1.41 | 2.08 | 38461 |
| 2026-01-21 | SNY | 46.19 | 1.37 | 0.42 | 39777 |
| 2026-01-22 | SNY | 46.53 | 1.30 | 0.44 | 41014 |
| 2026-01-23 | SNY | 47.2 | 1.30 | 1.38 | 41373 |
| 2026-01-26 | SNY | 47.34 | 1.29 | 0.45 | 41969 |
| 2026-01-27 | SNY | 47.51 | 1.27 | 1.78 | 42941 |
| 2026-01-28 | SNY | 45.74 | 1.28 | 0.67 | 43541 |
| 2026-01-29 | SNY | 46.21 | 1.23 | 0.89 | 45570 |
| 2026-01-30 | SNY | 47.03 | 1.24 | 0.86 | 46634 |
| 2026-02-02 | SNY | 47.39 | 1.23 | 0.76 | 48638 |
| 2026-02-03 | SNY | 47.51 | 1.24 | 0.86 | 49138 |
| 2026-02-04 | SNY | 48.12 | 1.24 | 0.63 | 49202 |
| 2026-02-05 | SNY | 47.48 | 1.23 | 1.41 | 49782 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-07 | SNY | 48.37 | 18.3 | 3988.4 | 4.56 |
| 2026-01-08 | SNY | 48.10 | 18.3 | 3674.9 | 4.56 |
| 2026-01-09 | SNY | 49.00 | 18.3 | 3934.1 | 4.56 |
| 2026-01-12 | SNY | 47.60 | 18.3 | 3337.3 | 4.56 |
| 2026-01-13 | SNY | 47.19 | 18.3 | 3531.7 | 4.56 |
| 2026-01-14 | SNY | 47.90 | 18.3 | 4019.5 | 4.56 |
| 2026-01-15 | SNY | 47.47 | 18.3 | 3582.9 | 4.56 |
| 2026-01-16 | SNY | 46.61 | 24.3 | 3603.0 | 4.56 |
| 2026-01-20 | SNY | 45.76 | 24.6 | 3503.0 | 4.56 |
| 2026-01-21 | SNY | 46.16 | 24.6 | 4052.6 | 4.56 |
| 2026-01-22 | SNY | 46.53 | 24.6 | 3839.7 | 4.56 |
| 2026-01-23 | SNY | 47.19 | 24.6 | 3800.3 | 4.56 |
| 2026-01-26 | SNY | 47.35 | 24.6 | 3915.5 | 4.56 |
| 2026-01-27 | SNY | 47.49 | 24.6 | 3850.0 | 4.56 |
| 2026-01-28 | SNY | 45.79 | 24.6 | 3414.2 | 4.56 |
| 2026-01-29 | SNY | 46.21 | 24.6 | 3880.2 | 4.56 |
| 2026-01-30 | SNY | 47.01 | 24.6 | 3419.2 | 4.56 |
| 2026-02-02 | SNY | 47.27 | 24.6 | 3784.9 | 4.56 |
| 2026-02-03 | SNY | 47.51 | 3.6 | 3654.2 | 4.97 |
| 2026-02-04 | SNY | 48.11 | 3.6 | 4126.4 | 4.97 |
| 2026-02-05 | SNY | 47.48 | 3.6 | 3833.7 | 5.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-07 | SNY | 0 | 1.25 | 0.31 |
| 2026-01-08 | SNY | 0 | 1.25 | 0.31 |
| 2026-01-09 | SNY | 0 | 1.25 | 0.31 |
| 2026-01-12 | SNY | 0 | 1.16 | 0.31 |
| 2026-01-13 | SNY | 0 | 1.16 | 0.32 |
| 2026-01-14 | SNY | 0 | 1.16 | 0.32 |
| 2026-01-15 | SNY | 0 | 1.16 | 0.32 |
| 2026-01-16 | SNY | 0 | 1.16 | 0.32 |
| 2026-01-20 | SNY | 0 | 2.56 | 0.32 |
| 2026-01-21 | SNY | 0 | 2.56 | 0.32 |
| 2026-01-22 | SNY | 0 | 2.56 | 0.32 |
| 2026-01-23 | SNY | 0 | 2.56 | 0.32 |
| 2026-01-26 | SNY | 0 | 1.60 | 0.32 |
| 2026-01-27 | SNY | 0 | 1.60 | 0.32 |
| 2026-01-28 | SNY | 0 | 1.60 | 0.35 |
| 2026-01-29 | SNY | 0 | 1.60 | 0.35 |
| 2026-01-30 | SNY | 0 | 1.60 | 0.35 |
| 2026-02-02 | SNY | 0 | 1.56 | 0.35 |
| 2026-02-03 | SNY | 0 | 1.56 | 0.35 |
| 2026-02-04 | SNY | 0 | 1.56 | 0.35 |
| 2026-02-05 | SNY | 0 | 1.56 | 0.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
1.06
Avg. EPS Est. Next Quarter
1.1
Insider Transactions
Institutional Transactions
1.56
Beta
0.43
Average Sales Estimate Current Quarter
10015
Average Sales Estimate Next Quarter
10761
Fair Value
63.26
Quality Score
94
Growth Score
83
Sentiment Score
93
Actual DrawDown %
21
Max Drawdown 5-Year %
-33.5
Target Price
56.9
P/E
11.86
Forward P/E
8.96
PEG
1.18
P/S
2.32
P/B
1.41
P/Free Cash Flow
10.64
EPS
4.01
Average EPS Est. Cur. Y
5.01
EPS Next Y. (Est.)
5.31
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
17.57
Relative Volume
1.47
Return on Equity vs Sector %
-22.1
Return on Equity vs Industry %
-30.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.06
EBIT Estimation
3833.7
SanofiSector: Healthcare
Industry: Drug Manufacturers - General
Employees:
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
stock quote shares SNY – Sanofi Stock Price stock today
news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025
marketwatch SNY – Sanofi yahoo finance google finance
stock history SNY – Sanofi invest stock market
stock prices SNY premarket after hours
ticker SNY fair value insiders trading